PubMed 42. Folkman J: Angiogenesis-dependent diseases. Semin Oncol 2001, 28:536–542.PubMedCrossRef 43. Liekens S, De Clercq E, Neyts J: Angiogenesis: regulators

and clinical applications. Biochem Pharmacol 2001, 61:253–270.PubMedCrossRef 44. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y: Vascular endothelial AR-13324 cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427–1434.PubMedCrossRef 45. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997, 17:4015–4023.PubMed 46. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002, 62:625–631.PubMed 47. Macpherson GR, PD-1/PD-L1 inhibitor Ng SSW, Lakhani NJ, Price DK, Venitz J, Figg WD: Antiangiogenesis therapeutic strategies in prostate cancer. Cancer and Metastasis Reviews 2002, 21:93–106.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions The

authors contributed to this study as follows: QHZ and JWT designed the study; QHZ, CW and JXZ performed experiments; LW analyzed data; SHD prepared the figures; JWT and GQZ drafted the manuscript. All authors have read and approved the final manuscript.”
“Introduction Cancer remains one of the leading causes of death in the world. Despite advances in our understanding of molecular and cancer biology, the discovery of cancer biomarkers and the refinement of conventional surgical procedures, radiotherapy, and chemotherapy, the learn more overall survival rate from cancer has not significantly improved in the past two decades [1, 2]. Early noninvasive detection and characterization of solid tumors is a fundamental prerequisite for effective therapeutic intervention. Emerging molecular imaging

techniques now allow recognition of early biomarker and anatomical changes before manifestation of gross pathological changes [3–6]. The development Tau-protein kinase of novel approaches for in vivo imaging and personalized treatment of cancers is urgently needed to find cancer-specific markers, but there is still limited knowledge of suitable biomarkers. Sperm protein 17 (Sp17) was originally reported to be expressed exclusively in the testis. Its primary function is binding to the zona pellucida and playing a critical role in successful fertilization [7]. Expression of Sp17 in malignant cells was first described by Dong et al, who found the mouse homologue of Sp17 to be highly expressed in metastatic cell lines derived from a murine model of squamous cell carcinoma but not in the nonmetastatic parental line [8].